Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

For a blood-borne cancer therapeutic agent to be effective, it must cross the blood vessel
wall to reach cancer cells in adequate quantities, and it must overcome the resistance …

PURPOSE The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade
gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve …

Background Nearly all patients with newly diagnosed glioblastoma experience recurrence
following standard-of-care radiotherapy (RT)+ temozolomide (TMZ). The purpose of the …

Background Pediatric patients with diffuse intrinsic pontine glioma (DIPG) have a poor
prognosis, with a median survival of less than 1 year. Oncolytic viral therapy has been …

Highlights•This Clinical Practice Guideline provides management recommendations for
patients with brain metastases from solid tumours.•The guideline covers clinical and …

Abstract Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of
diffuse glioma,–. The most common IDH1 mutation in gliomas affects codon 132 and …

Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer.
Although great efforts have been made by clinicians and researchers, no significant …

Glioblastoma is the most common primary malignant brain tumor in adults and is associated
with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a …

Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt
from central tolerance, can generate robust immune responses, and can function as bona …